Complement System Activation In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The complement system is a critical component of the innate immune system that plays a dual role in neurodegeneration — both in normal immune surveillance and in pathological neuroinflammation. This pathway page covers the complement cascade, its activation in Alzheimer's Disease, Parkinson's Disease, ALS, and therapeutic targeting. [1]
The complement system consists of over 30 proteins that function in a cascade fashion to eliminate pathogens, clear cellular debris, and modulate immune responses. In the brain, complement proteins are produced by microglia, astrocytes, and neurons, where they participate in synaptic pruning, neurodevelopment, and inflammatory responses. [2]
| Receptor | Expression | Ligand | Function | [3]
|----------|------------|--------|----------| [4]
| C3aR | Neurons, microglia, astrocytes | C3a | Pro-inflammatory signaling | [5]
| C5aR1 | Microglia, neurons | C5a | Chemotaxis, neurotoxicity | [6]
| C5aR2 | Various cell types | C5a | Immunomodulation | [7]
| CR1/CD35 | Microglia | C3b/C4b | Clearance, phagocytosis | [8]
| CR3/CD11b | Microglia | C3b/iC3b | Phagocytosis of opsonized targets | [9]
| Drug | Target | Stage | Company |
|---|---|---|---|
| Avacopan | C5aR1 | Phase 3 | ChemoCentryx |
| Pegcetacoplan | C3 | Phase 2 | Apellis |
| Namilumab | C5 | Preclinical | Various |
| ANX005 | C1q | Phase 1 | Annexon |
| IFX-1 | C5a | Phase 2 | InflaRx |
The study of Complement System Activation In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 10 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 31%
Veerhuis R, et al. Complement and neurodegeneration. Mol Neurodegener. 2023. ↩︎
Stevens B, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2022. ↩︎
Zhou Y, et al. 'C1q in Alzheimer''s disease: From pathophysiology to therapeutic targeting'. Nat Rev Neurol. 2024. ↩︎
Lamerton RE, et al. 'Complement and Parkinson''s disease: Implications for treatment'. Mov Disord. 2023. ↩︎
Lee JD, et al. 'Complement in ALS: Pathogenic mechanisms and therapeutic potential'. Brain. 2024. ↩︎
Shi Q, et al. Complement C3 deficiency protects against neurodegeneration. Nat Neurosci. 2023. ↩︎
Lian H, et al. C5aR1 antagonism blocks complement-mediated synaptic loss. Neuron. 2024. ↩︎
Morgan BP. Complement in brain injury and disease. Brain. 2022. ↩︎
Ricklin D, et al. 'Complement therapeutics: From bench to bedside'. Nat Rev Immunol. 2023. ↩︎